Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1256 | 1.00 | TAAR1 (0.52) | TAAR1AOC3TRPA1RIPK1CYP2D6 | |
| SCHEMBL14191123 | 1.00 | TAAR1 (0.52) | TAAR1AOC3TRPA1RIPK1CYP2D6 | |
| SCHEMBL2312796 | 0.88 | GRIA4 (0.50) | TAAR1 | |
| SCHEMBL7562750 | 0.86 | TAAR1 (0.40) | TAAR1AOC3TRPA1RIPK1 | |
| SCHEMBL9580067 | 0.84 | HDAC4 (0.42) | TAAR1AOC3 | |
| SCHEMBL12611658 | 0.83 | TAAR1 (0.48) | TAAR1AOC3TRPA1RIPK1CYP2D6 | |
| SCHEMBL27562378 | 0.83 | TAAR1 (0.48) | TAAR1AOC3TRPA1RIPK1CYP2D6 | |
| SCHEMBL10350119 | 0.82 | TRPA1 (0.47) | TAAR1AOC3TRPA1RIPK1 | |
| SCHEMBL1299325 | 0.82 | TYR (0.52) | CYP2D6 | |
| SCHEMBL28250102 | 0.82 | HPGD (0.40) | TAAR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114349687-B | 3, 5-dicarboxylic ester-1, 4-dihydropyridine hydrogenation reagent, preparation method and application thereof | 中山奕安泰医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-114349685-B | 1, 4-dihydropyridine hydrogenation reagent, preparation method and application thereof | 中山奕安泰医药科技有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-114349686-B | 1, 4-dihydropyridine chiral hybrid hydrogenation reagent, preparation method and application thereof | 中山奕安泰医药科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2022077852-A1 | 3,5-DICARBOXYLIC ACID ESTER-1,4-DIHYDROPYRIDINE HYDROGENATING REAGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中山奕安泰医药科技有限公司 | 2022-04-21 | — | — | WO | disclosed |
| WO-2022077851-A1 | 1,4-DIHYDROPYRIDINE CHIRAL HYBRID HYDROGENATION REAGENT, PREPARATION METHOD AND APPLICATION THEREOF | 中山奕安泰医药科技有限公司 | 2022-04-21 | — | — | WO | disclosed |
| CN-114349685-A | 3, 5-diamide-1, 4-dihydropyridine hydrogenation reagent and preparation method and application thereof | 中山奕安泰医药科技有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114349687-A | 3, 5-dicarboxylic ester-1, 4-dihydropyridine hydrogenation reagent and preparation method and application thereof | 中山奕安泰医药科技有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114349686-A | 1, 4-dihydropyridine chiral hybrid hydrogenation reagent and preparation method and application thereof | 中山奕安泰医药科技有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-109824652-A | A kind of Isosorbide-5-Nitrae-dihydropyridines difunctionality chiral catalyst and its preparation method and application | 广西九圣新材料有限公司 | 2019-05-31 | — | — | CN | disclosed |
| EP-2438989-B1 | USE OF ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| CN-1990541-A | Crosslinkable compositions, process for their preparation and their use | LANXESS DEUTSCHLAND GMBH (DE) | 2007-07-04 | — | — | CN | disclosed |
| US-20070117859-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-05-24 | — | — | US | disclosed |
| US-7164019-B2 | Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC | ROCHE PALO ALTO LLC (US) | 2007-01-16 | — | — | US | disclosed |
| US-7153857-B2 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-20060229313-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | US | disclosed |
| US-20060161024-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-07-20 | — | — | US | disclosed |
| US-20040220185-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | US | disclosed |
| EP-1417201-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | AstraZeneca AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003014111-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2003-02-20 | — | — | WO | disclosed |
| CN-1390219-A | Pyrazolopyrimidines as therapeutic agents | ABBOTT AG (DE) | 2003-01-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229313-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | TAAR1 1051/4885AOC3 279/4885TRPA1 1522/4885 |
| US-20040220185-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | TAAR1 752/4885AOC3 296/4885TRPA1 1461/4885 |
| US-20060161024-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | ECH1, CBR1, DHCR24 | TAAR1 3847/4885AOC3 487/4885TRPA1 1321/4885 |
| US-20070117859-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | TAAR1 735/4885AOC3 1468/4885TRPA1 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.